Evolutionary Therapy for Rhabdomyosarcoma

Status Recruiting

Clinical Trial Summary

This clinical trial will evaluate 4 different strategies of chemotherapy schedules in newly diagnosed participants with metastatic Fusion Positive (alveolar) Rhabdomyosarcoma. The participant and their physician will choose from: Arm A) a first strike therapy, Arm B) a first strike-second strike (maintenance) therapy, Arm C) an adaptively timed therapy, and Arm D) conventional chemotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Rhabdomyosarcoma

Clinical Trial Details

NCT number	NCT04388839
Study type	Interventional
Source	H. Lee Moffitt Cancer Center and Research Institute
Contact	Jessica Crimella, BSN, RN
Phone	813-745-6250
Email	Jessica.Crimella@moffitt.org
Status	Recruiting
Phase	Phase 2
Start date	September 27, 2020
Completion date	December 2027

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04906876` - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas	Phase 2
Completed	`NCT01674101` - Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy	N/A
Completed	`NCT00520936` - A Study of Pemetrexed in Children With Recurrent Cancer	Phase 2
Completed	`NCT03655587` - Impact of an Orthotic Intervention in Children With Peripheral Neuropathy	N/A
Recruiting	`NCT06094101` - Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)	Phase 1/Phase 2
Recruiting	`NCT04625907` - FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma	Phase 1/Phase 2
Active, not recruiting	`NCT04095221` - A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma	Phase 1/Phase 2
Completed	`NCT01661400` - Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors	Phase 1
Recruiting	`NCT04337177` - Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors	Phase 1
Active, not recruiting	`NCT02945800` - Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma	Phase 2
Not yet recruiting	`NCT06029465` - Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials
Terminated	`NCT02536183` - A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors	Phase 1
Recruiting	`NCT00592592` - Proton RT for the Treatment of Pediatric Rhabdomyosarcoma	Phase 2
Completed	`NCT00187174` - Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors	Phase 1
Completed	`NCT01505569` - Auto Transplant for High Risk or Relapsed Solid or CNS Tumors	N/A
Active, not recruiting	`NCT03220035` - Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Completed	`NCT05093322` - A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors	Phase 1/Phase 2
Completed	`NCT04956198` - Drug Sensitivity and Mutation Profiling
Recruiting	`NCT04791228` - A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors	Phase 2
Active, not recruiting	`NCT03709680` - Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors	Phase 1/Phase 2